Literature DB >> 1596236

Protective effects of flunarizine on ischemic injury in the rat retina.

K Takahashi1, T T Lam, D P Edward, E R Buchi, M O Tso.   

Abstract

Intracellular calcium overload has been implicated to be a major factor in triggering cell death after ischemic neuronal injury. We investigated the effects of flunarizine hydrochloride, a calcium-overload blocker, on pressure-induced retinal ischemia in a rat model. Retinal ischemia was induced in intraocular pressure to 110 mm Hg for 45 minutes. Two regimens of treatment with flunarizine were examined: (1) prophylactic treatment, in which flunarizine was administered before ischemia and in the early phase of reperfusion; and (2) postischemic treatment, in which flunarizine was administered only in the early phase of reperfusion. Injury was evaluated morphologically and morphometrically by measuring the thickness of the inner retinal layers on plastic-embedded retinal sections and by counting the retinal ganglion cells on retinal flat preparations. By morphologic and morphometric criteria, a significant but partial protection of the inner retinal layers was noted in the groups given either regimen. This protective effect of flunarizine suggests that elevated intracellular calcium concentration may play an important role in ischemic retinal injury.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1596236     DOI: 10.1001/archopht.1992.01080180134041

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  12 in total

Review 1.  [Characteristic features of optic nerve ganglion cells and approaches for neuroprotection. From intracellular to capillary processes and therapeutic considerations].

Authors:  R H W Funk; K-G Schmidt
Journal:  Ophthalmologe       Date:  2004-11       Impact factor: 1.059

2.  High intraocular pressure-induced ischemia and reperfusion injury in the optic nerve and retina in rats.

Authors:  M Adachi; K Takahashi; M Nishikawa; H Miki; M Uyama
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-07       Impact factor: 3.117

3.  Functions of the two glutamate transporters GLAST and GLT-1 in the retina.

Authors:  T Harada; C Harada; M Watanabe; Y Inoue; T Sakagawa; N Nakayama; S Sasaki; S Okuyama; K Watase; K Wada; K Tanaka
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

4.  Neuroprotective effect of the novel Na+/Ca2+ channel blocker NS-7 on rat retinal ganglion cells.

Authors:  Shinichiro Saito; Masaaki Ohashi; Akira Naito; Yasuhiro Fukaya; Yasuyuki Suzuki; Makoto Araie
Journal:  Jpn J Ophthalmol       Date:  2005 Sep-Oct       Impact factor: 2.447

5.  Diltiazem-induced neuroprotection in glutamate excitotoxicity and ischemic insult of retinal neurons.

Authors:  Géraldine Vallazza-Deschamps; Céline Fuchs; David Cia; Luc-Henri Tessier; José A A Sahel; Henri Dreyfus; Serge Picaud
Journal:  Doc Ophthalmol       Date:  2005-01       Impact factor: 2.379

6.  Activation of autophagy in a rat model of retinal ischemia following high intraocular pressure.

Authors:  Antonio Piras; Daniele Gianetto; Daniele Conte; Alex Bosone; Alessandro Vercelli
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

Review 7.  Neuroprotective therapies for glaucoma.

Authors:  Wei Song; Ping Huang; Chun Zhang
Journal:  Drug Des Devel Ther       Date:  2015-03-11       Impact factor: 4.162

8.  The Regulatory NOD-Like Receptor NLRC5 Promotes Ganglion Cell Death in Ischemic Retinopathy by Inducing Microglial Pyroptosis.

Authors:  Yang Deng; Yunzhao Fu; Longxiang Sheng; Yixin Hu; Lishi Su; Jiawen Luo; Chun Yan; Wei Chi
Journal:  Front Cell Dev Biol       Date:  2021-05-20

9.  Neurodegenerative diseases of the retina and potential for protection and recovery.

Authors:  K-G Schmidt; H Bergert; R H W Funk
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

Review 10.  Current perspective of neuroprotection and glaucoma.

Authors:  Kailin Tian; Shannon Shibata-Germanos; Milena Pahlitzsch; M Francesca Cordeiro
Journal:  Clin Ophthalmol       Date:  2015-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.